| Market Cap | 4.59M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -3.71M | Forward P/E | -3.41 | EPS next Y | - | 50D Avg Chg | -20.00% |
| Sales | 2.28M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -44.00% |
| Dividend | N/A | Price/Book | 2.08 | EPS next 5Y | - | 52W High Chg | -81.00% |
| Recommedations | 2.00 | Quick Ratio | 1.51 | Shares Outstanding | 2.78M | 52W Low Chg | - |
| Insider Own | 0.42% | ROA | -30.63% | Shares Float | 2.54M | Beta | 1.28 |
| Inst Own | 12.01% | ROE | -102.78% | Shares Shorted/Prior | 2.71K/10.10K | Price | 2.76 |
| Gross Margin | 67.32% | Profit Margin | -162.55% | Avg. Volume | 5,380 | Target Price | - |
| Oper. Margin | -29.06% | Earnings Date | May 13 | Volume | 6,068 | Change | -6.06% |
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. It sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, Australia, India, and internationally. The company was incorporated in 2003 and is headquartered in Elmsford, New York.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Cassirer Aurora | Director Director | Jun 01 | Buy | 0.69 | 2,000 | 1,380 | 2,000 | 06/02/22 |